R3 Vascular

About R3 Vascular

R3 Vascular Inc. is a privately-held medical device company, founded in 2019 and operating from Mountain View, California, with additional facilities in Munich, Germany. The company is focused on addressing the significant unmet needs in the treatment of peripheral artery disease (PAD) below the knee, a condition affecting millions globally and a market projected to reach $17.4 billion by 2030.

The company was established by Kamal Ramzipoor, a seasoned executive in the medical device sector with over 30 years of experience and more than 150 patents to his name. His background in developing and commercializing polymer-based drug/device combination products directly informs the company's core technology. In May 2024, Ramzipoor transitioned to the role of Chief Technology Officer, with veteran medtech executive Christopher M. Owens appointed as President and CEO to guide the company through its next growth phase. Owens brings extensive experience from previous leadership roles, including at IDEV Technologies, which also focused on the peripheral vascular market and was acquired by Abbott.

R3 Vascular's primary product is the MAGNITUDE® Bioresorbable Sirolimus-Eluting Scaffold. This device is engineered to treat complex lesions in arteries below the knee by providing temporary, stent-like mechanical support to the vessel while delivering the anti-inflammatory drug sirolimus to promote healing. Its key differentiator lies in its construction from a unique, ultra-high molecular weight polylactic acid polymer, which allows the scaffold to be thinner, stronger, and more flexible than previous options. The scaffold is designed to be completely and predictably absorbed by the body over time, leaving behind a more naturally functioning vessel.

The company's business model revolves around the development, clinical validation, and eventual commercialization of its proprietary scaffold technology. R3 Vascular has successfully raised significant capital, including a Series A round in 2020 and a substantial $87 million Series B round in May 2024. This funding, led by investors like Deerfield Management and 415 Capital, is allocated to support the ELITE-BTK pivotal trial, scale up manufacturing, and pursue global regulatory submissions, including a PMA market application with the FDA. The company achieved key milestones in 2025 by treating the first patient in its pivotal trial and securing Medicare coverage for the study, signaling strong progress toward market entry.